Literature DB >> 10425290

Chemoimmunosensitization of the T24 human bladder cancer line to Fas-mediated cytotoxicity and apoptosis by cisplatin and 5-fluorouracil.

Y Mizutani1, X X Wu, O Yoshida, T Shirasaka, B Bonavida.   

Abstract

Previous studies have demonstrated that cisplatin (CDDP) sensitizes bladder cancer cells to Fas-mediated cytotoxicity and that CDDP also enhances the cytotoxic effect of 5-fluorouracil (5-FU). These agents mediate apoptosis and may share common intracellular pathways leading to cell killing. We reasoned that combination treatment with CDDP, 5-FU and anti-Fas monoclonal antibody (mAb) might overcome the drug-resistance. We investigated whether CDDP, 5-FU and anti-Fas mAb synergize in cytotoxicity and apoptosis against the T24 bladder cancer line. Cytotoxicity was monitored by a one day microculture tetrazolium dye assay. Treatment of T24 cells with anti-Fas mAb in combination with CDDP or 5-FU resulted in a synergistic cytotoxic effect. In addition, combination treatment of T24 cells with CDDP, 5-FU and anti-Fas mAb further enhanced the synergistic cytotoxicity achieved by two agents. The synergy achieved in cytotoxicity with CDDP, 5-FU and anti-Fas mAb was also achieved in apoptosis. The current study demonstrates that combination treatment of bladder cancer cells with CDDP, 5-FU and anti-Fas mAb overcomes their resistance. In addition, the sensitization required low concentrations of CDDP and 5-FU, and thus supporting the potential in vivo application of combination of CDDP, 5-FU and immunotherapy in the treatment of drug-resistant bladder cancer.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10425290     DOI: 10.3892/or.6.5.979

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  4 in total

Review 1.  Conceptual changes in cancer chemotherapy: from an oral fluoropyrimidine prodrug, UFT, to a novel oral fluoropyrimidine prodrug, S-1, and low-dose FP therapy in Japan.

Authors:  T Shirasaka; S Yamamitsu; A Tsuji; T Taguchi
Journal:  Invest New Drugs       Date:  2000-11       Impact factor: 3.850

Review 2.  Enhancing efficacy of therapeutic vaccinations by combination with other modalities.

Authors:  James L Gulley; Ravi A Madan; Philip M Arlen
Journal:  Vaccine       Date:  2007-06-04       Impact factor: 3.641

3.  Up-regulation of Fas reverses cisplatin resistance of human small cell lung cancer cells.

Authors:  Wei Wu; Hai-Dong Wang; Wei Guo; Kang Yang; Yun-ping Zhao; Yao-guang Jiang; Ping He
Journal:  J Exp Clin Cancer Res       Date:  2010-05-14

4.  Combining Vaccines with Conventional Therapies for Cancer.

Authors:  Philip M Arlen; Ravi A Madan; James W Hodge; Jeffrey Schlom; James L Gulley
Journal:  Update Cancer Ther       Date:  2007-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.